{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:57:05Z","timestamp":1782431825213,"version":"3.54.5"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Small cell bladder cancer (SCBC) is a rare histologic variant of bladder cancer with an aggressive disease course and poor outcomes. Given its uncommon nature, there is a paucity of high-quality data characterizing genomic drivers of this disease, and most patients are treated with approaches mirroring small cell lung cancer (SCLC). Leveraging the Tempus Lens deidentified clinically annotated genomic data set, we sought to evaluate the mutational landscape of SCBC relative to urothelial carcinoma (UC) and SCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Somatic pathogenic genomic alterations in patients with SCBC, UC, and SCLC of any stage who underwent blood- or tissue-based genomic profiling through the Tempus assay were cataloged. Baseline clinical and demographic features were compared across histologic groups. Alterations were collated and summarized using descriptive statistics. Pairwise comparisons were performed to assess differences in mutation frequency across pathologic cohorts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              In total, 149 SCBC, 4,350 UC, and 1,697 SCLC patients were included in the study. The most common genomic alterations in SCBC were in\n              <jats:italic>TP53<\/jats:italic>\n              (87%),\n              <jats:italic>TERT<\/jats:italic>\n              (75%), and\n              <jats:italic>RB1<\/jats:italic>\n              (70%). Among SCBC patients with\n              <jats:italic>TP53<\/jats:italic>\n              mutations,\n              <jats:italic>RB1<\/jats:italic>\n              comutations were observed in 77% of patients. Compared with UC, SCBC patients were significantly enriched for\n              <jats:italic>TP53<\/jats:italic>\n              ,\n              <jats:italic>RB1<\/jats:italic>\n              ,\n              <jats:italic>KMT2D<\/jats:italic>\n              , and\n              <jats:italic>KDM6A<\/jats:italic>\n              mutations. Compared with SCLC, SCBC patients were enriched for\n              <jats:italic>TERT<\/jats:italic>\n              ,\n              <jats:italic>ARID1A<\/jats:italic>\n              , and\n              <jats:italic>CREBBP<\/jats:italic>\n              mutations, among others (\n              <jats:italic>P<\/jats:italic>\n              &lt; .05). Multiple clinically targetable mutations were observed in SCBC, including\n              <jats:italic>PIK3CA<\/jats:italic>\n              (19%),\n              <jats:italic>ERBB2\/3<\/jats:italic>\n              (13%), and\n              <jats:italic>ALK<\/jats:italic>\n              (10%). Limitations of this study include its retrospective nature.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>This study represents one of the most extensive efforts to characterize SCBC to date, providing a novel understanding of the genomic alterations underlying the disease and revealing actionable mutations that could serve as potential targets for improved clinical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po-24-00947","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T19:59:11Z","timestamp":1744315151000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4334-1300","authenticated-orcid":true,"given":"Salvador","family":"Jaime-Casas","sequence":"first","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal S.","family":"Chawla","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-7714","authenticated-orcid":true,"given":"Nicholas J.","family":"Salgia","sequence":"additional","affiliation":[{"name":"Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-9514","authenticated-orcid":true,"given":"Benjamin","family":"Mercier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-8524","authenticated-orcid":true,"given":"Ameish","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-9821","authenticated-orcid":true,"given":"Daniela V.","family":"Castro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3647-7356","authenticated-orcid":true,"given":"Hedyeh","family":"Ebrahimi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3114-0642","authenticated-orcid":true,"given":"Regina","family":"Barragan-Carrillo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-380X","authenticated-orcid":true,"given":"Peter D.","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-8144","authenticated-orcid":true,"given":"Alexis","family":"LeVee","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2181-8405","authenticated-orcid":true,"given":"Miguel","family":"Zugman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-8513","authenticated-orcid":true,"given":"Nazli","family":"Dizman","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-297X","authenticated-orcid":false,"given":"Luis","family":"Meza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2751-5915","authenticated-orcid":true,"given":"Zeynep","family":"Zengin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-4527","authenticated-orcid":true,"given":"Alexander","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":true,"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":true,"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5198-0673","authenticated-orcid":true,"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology &amp; Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26197"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.05.005"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62369-3"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q"},{"key":"e_1_3_5_6_2","article-title":"Molecular profiling of small cell bladder cancer","volume":"33","author":"Wang J","year":"2015","unstructured":"Wang J, Arguello D, Gatalica Z, et al: Molecular profiling of small cell bladder cancer. J Clin Oncol 33, 2015 (suppl 7; abstr 338)","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo CC","year":"2024","unstructured":"Guo CC, Lee S, Lee JG, et al: Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol 21:391-405, 2024","journal-title":"Nat Rev Urol"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810215)47:4<724::AID-CNCR2820470417>3.0.CO;2-2"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.09.005"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_5_11_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA1","article-title":"Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN bladder 100 phase III interim analysis","volume":"38","author":"Powles T","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al: Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN bladder 100 phase III interim analysis. J Clin Oncol 38, 2020 (suppl 7; abstr LBA1)","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03091"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03489"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.08.033"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26797"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2655"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.017"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-014-0047-7","article-title":"High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins","volume":"7","author":"Zheng X","year":"2014","unstructured":"Zheng X, Zhuge J, Bezerra SM, et al: High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 7:47, 2014","journal-title":"J Hematol Oncol"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2498"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1006\/scdb.1998.0260","article-title":"Structural conservation of Notch receptors and ligands","volume":"9","author":"Fleming RJ","year":"1998","unstructured":"Fleming RJ: Structural conservation of Notch receptors and ligands. Semin Cell Dev Biol 9:599-607, 1998","journal-title":"Semin Cell Dev Biol"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0471"},{"key":"e_1_3_5_34_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.04.002","article-title":"Lurbinectedin for metastatic small-cell bladder carcinoma","volume":"151","author":"Boudin L","year":"2021","unstructured":"Boudin L, Patient M, Romeo E, et al: Lurbinectedin for metastatic small-cell bladder carcinoma. Eur J Cancer 151:1-2, 2021","journal-title":"Eur J Cancer"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114248"},{"key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/1078-0432.CCR-17-3646","article-title":"Small-cell neuroendocrine tumors: Cell state trumps the oncogenic driver","volume":"24","author":"Oser MG","year":"2018","unstructured":"Oser MG, J\u00e4nne PA: Small-cell neuroendocrine tumors: Cell state trumps the oncogenic driver. Clin Cancer Res 24:1775-1776, 2018","journal-title":"Clin Cancer Res"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-24-00947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T19:59:14Z","timestamp":1744315154000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-24-00947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1200\/PO-24-00947"],"URL":"https:\/\/doi.org\/10.1200\/po-24-00947","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400947"}}